Systemic administration of attenuated Salmonella typhimurium in combination with interleukin-21 for cancer therapy

Wang,Yuxuan; Chen,Jianxiang; Tang,Bo; Zhang,Xiangyu; Hua,Zi-Chun

doi:10.3892/mco.2013.90

Systemic administration of attenuated Salmonella typhimurium in combination with interleukin-21 for cancer therapy

Authors:
- Yuxuan Wang
- Jianxiang Chen
- Bo Tang
- Xiangyu Zhang
- Zi-Chun Hua
View Affiliations

Affiliations: The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, Jiangsu 210093, P.R. China, Changzhou High-Tech Research Institute of Nanjing University and Jiangsu TargetPharma Laboratories Inc., Changzhou 213164, P.R. China
Published online on: March 11, 2013 https://doi.org/10.3892/mco.2013.90
Pages: 461-465

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Attenuated Salmonella typhimurium (S. typhimurium) strain VNP20009 has been employed as a powerful anticancer agent due to its selective accumulation in tumors for targeted therapy. S. typhimurium has been demonstrated to constitute a delivery tool carrying antiangiogenic or proapoptotic genes that treat cancer. The hydrodynamic tail vein (HTV) injection of naked plasmid DNA has been developed as an effective gene delivery strategy, which has been successfully used in vivo. The aim of this study was to develop a combination therapy of S. typhimurium VNP20009 and HTV injection of interleukin-21 (IL-21) expression plasmid to evaluate the antitumor potential on an experimental melanoma model. Consistent with previous results, single VNP20009 treatment was demonstrated to possess effective activities to suppress tumor growth and prolong animal survival. Moreover, HTV injection of IL-21 plasmid promoted the antitumor activities of VNP20009. The mice that were administered combined therapy exhibited smaller tumor sizes and longer survival time compared with those administered VNP20009 or IL-21 treatment alone. IL-21 induced more infiltrating natural killer (NK) and T cells to the tumor area. These findings indicated that S. typhimurium in combination with IL-21 promotes antitumor immune responses, suggesting a novel strategy in the treatment of cancer.

View Figures

View References

1.	Dachs GU, Patterson AV, Firth JD, et al: Targeting gene expression to hypoxic tumor cells. Nat Med. 3:515–520. 1997. View Article : Google Scholar : PubMed/NCBI
2.	Pouyssegur J, Dayan F and Mazure NM: Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 441:437–443. 2006. View Article : Google Scholar : PubMed/NCBI
3.	Brown JM and Giaccia AJ: The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58:1408–1416. 1998.PubMed/NCBI
4.	Graham CH, Forsdike J, Fitzgerald CJ and MacDonald-Goodfellow S: Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer. 80:617–623. 1999. View Article : Google Scholar : PubMed/NCBI
5.	Leschner S and Weiss S: Salmonella-allies in the fight against cancer. J Mol Med (Berl). 88:763–773. 2010. View Article : Google Scholar : PubMed/NCBI
6.	Luo X, Li Z, Lin S, et al: Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models. Oncol Res. 12:501–508. 2001. View Article : Google Scholar : PubMed/NCBI
7.	Pawelek JM, Low KB and Bermudes D: Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 57:4537–4544. 1997.PubMed/NCBI
8.	Chen J, Wei D, Zhuang H, et al: Proteomic screening of anaerobically regulated promoters from Salmonella and its antitumor applications. Mol Cell Proteomics. 10:M111.0093992011. View Article : Google Scholar : PubMed/NCBI
9.	Jia LJ, Wei DP, Sun QM, Jin GH, et al: Tumor-targeting Salmonella typhimuriumimproves cyclophosphamide chemotherapy at maximum tolerated dose and low-dose metronomic regimens in a murine melanoma model. Int J Cancer. 121:666–674. 2007.PubMed/NCBI
10.	Chen G, Tang B, Yang BY, Chen JX, et al: Tumor-targeting Salmonella typhimurium, a natural tool for activation of prodrug 6MePdR and their combination therapy in murine melanoma model. Appl Microbiol Biotechnol. Aug 7–2012, (Epub ahead of print).
11.	Chen J, Yang B, Cheng X, et al: Salmonella-mediated tumor-targeting TRAIL gene therapy significantly suppresses melanoma growth in mouse model. Cancer Sci. 103:325–333. 2012. View Article : Google Scholar : PubMed/NCBI
12.	Spolski R and Leonard WJ: Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol. 26:57–79. 2008. View Article : Google Scholar : PubMed/NCBI
13.	Sondergaard H and Skak K: IL-21: roles in immunopathology and cancer therapy. Tissue Antigens. 74:467–479. 2009. View Article : Google Scholar : PubMed/NCBI
14.	Goluboff ET, Hirano D, Thrasher JB, Stark G, Miller GJ and Glode LM: New approaches to the treatment of advanced prostate cancer. Rev Urol. 3:S69–S78. 2001.PubMed/NCBI
15.	Patyar S, Joshi R, Byrav DS, Prakash A, Medhi B and Das BK: Bacteria in cancer therapy: a novel experimental strategy. J Biomed Sci. 17:212010. View Article : Google Scholar : PubMed/NCBI
16.	Low KB, Ittensohn M, Luo X, et al: Construction of VNP20009: a novel, genetically stable antibiotic-sensitive strain of tumor-targeting Salmonella for parenteral administration in humans. Methods Mol Med. 90:47–60. 2004.
17.	Dang LH, Bettegowda C, Huso DL, Kinzler KW and Vogelstein B: Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA. 98:15155–15160. 2001. View Article : Google Scholar : PubMed/NCBI
18.	Stolfi C, Pallone F, Macdonald TT and Monteleone G: Interleukin-21 in cancer immunotherapy: friend or foe? Oncoimmunology. 1:351–354. 2012. View Article : Google Scholar : PubMed/NCBI
19.	Stolfi C, Rizzo A, Franze E, et al: Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J Exp Med. 208:2279–2290. 2011. View Article : Google Scholar : PubMed/NCBI
20.	Jauch D, Martin M, Schiechl G, et al: Interleukin 21 controls tumour growth and tumour immunosurveillance in colitis-associated tumorigenesis in mice. Gut. 60:1678–1686. 2011. View Article : Google Scholar : PubMed/NCBI
21.	Hodges BL and Scheule RK: Hydrodynamic delivery of DNA. Expert Opin Biol Ther. 3:911–918. 2003. View Article : Google Scholar
22.	Romero NB, Benveniste O, Payan C, et al: Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part II: clinical protocol. Neuromuscul Disord. 12:S45–S48. 2002. View Article : Google Scholar
23.	Budker V, Zhang G, Knechtle S and Wolff JA: Naked DNA delivered intraportally expresses efficiently in hepatocytes. Gene Ther. 3:593–598. 1996.PubMed/NCBI